



Mantle Cell Lymphoma

Xenograft Tumor Model

| MODEL | NOMENCLATURE | HAIR | T CELLS | B CELLS | NK CELLS |
|-------|--|------|---------------|---------------|-----------------|
| SHrN® | NOD.Cg- <i>Prkdc^{scid}Hr^{hr}/</i> NCrHsd | No | Nonfunctional | Nonfunctional | Impaired |

MODEL

The SHrN® is a Hairless NOD.SCID Mouse developed by Harlan. Harlan became Envigo in 2015, then Envigo was acquired by Inotiv in 2021. The SHrN® is a triple-immunodeficient model with distinct benefits and excellent for tumor xenografts.


CELL LINE

Human JeKo-1 cells sourced from ATCC[®] (Number: CRL-3006[™]) were implanted into a cohort of SHrN[®] mice. Female mice at approximately 8 weeks of age were implanted with 1.0e7 cells with GFR Matrigel into the subcutaneous space of the right flank.

TUMOR GROWTH IN VIVO

The mice were maintained in a barrier under controlled environmental conditions. The mice consumed Teklad Global Rodent Diet 2914 (14% protein). Body weights were taken and tumor measurements were assessed with a caliper twice per week.

Tumor Growth Rate for JeKo-1 Cells Inoculated into Female SHrN[®] Mice



Tumor growth study services conducted by Labcorp Drug Development